Loading data for GERN — first visit, this takes a few seconds.

알림

Geron Corporation (GERN)

NasdaqGS: GERN · 실시간 가격 · USD

1.55

-0.04 (-2.52%)

종가 기준: Aug 20, 2026, 8:00 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-2.52% (1D)

데이터 없음

매수호가	1.33
시가총액	995.83M
매출 (ttm)	204.56M
순이익 (ttm)	-67.61M
	0.59
	-0.11
	n/a
	38.75
P/B (ttm)	4.56
P/S (ttm)	4.87
실적 발표일	May 6, 2026

매도호가	1.56
거래량	5,987,357
평균 거래량 (20일)	11,670,120
시가	1.58
전일 종가	1.59
일중 범위	1.54 - 1.59
52주 범위	1.04 - 2.01
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

GERN 소개

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 31, 1996

직원 수 258

상장 거래소 NasdaqGS

티커 GERN

웹사이트 https://www.geron.com

전체 기업 정보

재무 실적

2025년 Geron의 매출은 183.88M로, 전년 76.99M 대비 138.83% 증가했습니다. 순이익은 -83.5M로, -52.17% 감소했습니다.

재무제표

어닝 서프라이즈

Geron가 Aug 5, 2026에 분기 실적을 발표했습니다:

매출 $57.48M 예상치 하회 $0, 및 17.22% 전년 대비 성장.

EPS -0.02 예상치 하회 -0.01, 및 33.33% 전년 대비 성장.

다음 실적 발표

Geron Corporation의 실적 발표 예정일은 May 6, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Simply Wall St.

Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns

Geron stock has recovered over the past year but is still sitting on a steep decline over three years, while the valuation checks currently lean toward the shares looking inexpensive relative to funda...

1주 전 · Simply Wall St.

Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative

Why Geron Stock Is Back in Focus After Fresh Guidance Geron (GERN) has drawn fresh attention after issuing 2026 earnings guidance tied to RYTELO net product revenue and releasing second quarter and ha...

1주 전 · Simply Wall St.

Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed?

In the second quarter of 2026, Geron Corporation reported revenue of US$57.48 million versus US$49.04 million a year earlier, a net loss of US$16.68 million, first-half revenue of US$109.32 million, a...

2주 전 · Motley Fool

Geron (GERN) Q2 2026 Earnings Call Transcript

RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.

2주 전 · GuruFocus.com

Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Geron Corp (GERN) reports 17% year-over-year net revenue growth, raises full-year guidance, and progresses regulatory discussions for its IMPACT MF trial.

2 페이지 중 1

Geron Corporation (GERN)